CHICAGO — The duration of symptoms before surgery for degenerative cervical myelopathy (DCM) plays a key role in the quality of the outcome, underscoring the need for increased awareness among ...

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal ...

At Toronto Western Hospital, neurosurgeon Dr. Michael Fehlings frequently encounters patients with degenerative cervical myelopathy (DCM), whose disabilities might have been avoided, if only they had ...

For patients with degenerative cervical myelopathy, some imaging techniques could act as a marker for a potentially reversible phase of the disease in which substantial clinical improvement can be ...

LA JOLLA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange ...

In August 2018, MediciNova, Inc. (MNOV) announced plans to conduct a Phase 2/3 trial of MN-166 in degenerative cervical myelopathy (DCM) through an agreement with the University of Cambridge and ...

On February 22, 2022, MediciNova, Inc. (NASDAQ:MNOV) announced that a recent publication identified MN-166 (ibudilast) as a promising pharmacological agent for the treatment of alcohol use disorder ...

Reston, Va. (September 4, 2013) – For patients with degenerative cervical myelopathy, imaging with 18F-FDG positron emission tomography (PET) could act as a marker for a potentially reversible phase ...